Evidence map›Paper›PMID 32108133›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2020

Synaptotagmin 12 (SYT12) Gene Expression Promotes Cell Proliferation and Progression of Lung Adenocarcinoma and Involves the Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.

Kaichao Liu, Jing Luo, Chenye Shao, Zhijian Ren, Sai Sun, Yihao Zhu, Hai Zhou, Zhisheng Jiang, Xiaokun Li, Wenfeng Gu and 6 more

Open access · hybridAbstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Kaichao LiuDepartment of Cardiothoracic Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China (mainland).
Jing LuoDepartment of Cardiothoracic Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China (mainland).
Chenye ShaoDepartment of Cardiothoracic Surgery, Jingling Hospital, Jingling School of Clinical Medicine, Nanjing Medical University, Nanjing, Jiangsu, China (mainland).
Zhijian RenJiangsu Key Laboratory of Molecular and Translational Cancer Research, Nanjing, Jiangsu, China (mainland).
Sai SunDepartment of Thoracic Surgery, Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Cancer Hospital, Cancer Institute of Jiangsu Province, Nanjing, Jiangsu, China (mainland).
Yihao ZhuThe Fourth Clinical College of Nanjing Medical University, Nanjing, Jiangsu, China (mainland).
Hai ZhouDepartment of Cardiothoracic Surgery, Jingling Hospital, Jingling School of Clinical Medicine, Nanjing Medical University, Nanjing, Jiangsu, China (mainland).
Zhisheng JiangDepartment of Cardiothoracic Surgery, Jinling Hospital, Nanjing, Jiangsu, China (mainland).
Xiaokun LiDepartment of Cardiothoracic Surgery, Jinling Hospital, Jinling Hospital, China (mainland).
Wenfeng GuDepartment of Cardiothoracic Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China (mainland).
Youtao XuJiangsu Key Laboratory of Molecular and Translational Cancer Research, Nanjing, Jiangsu, China (mainland).
Yong QiangDepartment of Cardiothoracic Surgery, Jinling Hospital, Nanjing, Jiangsu, China (mainland).
Binhui RenJiangsu Key Laboratory of Molecular and Translational Cancer Research, Nanjing, Jiangsu, China (mainland).
Lin XuJiangsu Key Laboratory of Molecular and Translational Cancer Research, Nanjing, Jiangsu, China (mainland).
Haiwei WuDepartment of Cardiothoracic Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China (mainland).
Yi ShenDepartment of Cardiothoracic Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China (mainland).
Jiangsu Cancer Hospital · CNNanjing University · CNNanjing General Hospital of Nanjing Military Command · CNNanjing Medical University · CNJinling Institute of Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND This study aimed to use bioinformatics analysis to compare data from tissue microarrays from patients with lung adenocarcinoma (LUAD) and normal lung tissue, and human lung adenocarcinoma cells with normal lung epithelial cells in vitro to investigate the role of synaptotagmin 12 (SYT12) gene expression in LUAD. MATERIAL AND METHODS Human lung adenocarcinoma cell lines (A549, SPC-A-1, H1299, H1975, and PC9) and the normal HBE cell line were compared, and tumor xenografts were developed in mice. The Cancer Genome Atlas (TCGA) tissue microarray data were used to compare SYT12 expression and overall survival (OS). The in vivo and in vitro effects of down-regulation and upregulation of SYT12 were studied using short-interfering RNA (si-RNA) and overexpression plasmids, respectively. The Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) pathway analysis, quantitative reverse transcription-polymerase chain reaction (qRT-PCR), and Western blot investigated the molecular mechanisms of SYT12 expression in LUAD. RESULTS SYT12 expression was increased in tissues from patients with LUAD from TCGA and was associated with advanced tumor stage and reduced prognosis. Knockdown of SYT12 suppressed the proliferation and migration of LUAD cells, and upregulation of SYT12 increased the proliferation and migration of LUAD cells in vitro. Phosphorylation of PIK3R3 activated the PI3K/AKT/mTOR pathway. In the mouse xenograft model, expression of SYT12 increased the volume and weight of the xenograft tumors. CONCLUSIONS Bioinformatics analysis, human LUAD cells, and mouse xenograft studies showed that SYT12 acted as a possible oncogene by phosphorylation of PIK3R3 to activate the PI3K/AKT/mTOR signaling pathway.

Indexed as

Adenocarcinoma of LungAdultAgedAged, 80 and overAnimalsCell Line, TumorCell MovementCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansLung NeoplasmsMaleMiceMice, NudeMicroRNAsMicroRNAsMTOR protein, humanPhosphatidylinositol 3-KinasePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSynaptotagminsTOR Serine-Threonine Kinases

Identifiers

PMID32108133
PMCPMC7063850
OpenAlexW3001702731

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.